AtriCure Marks First AtriClip FLEX-Mini Treatment

The first patient has been treated with AtriCure Inc.’s U.S. Food and Drug Administration (FDA)-cleared AtriClip FLEX-Mini device, reportedly the smallest profile surgical left atrial appendage (LAA) device on the market.

The AtriClip FLEX-Mini builds upon the proven technology of AtriCure’s AtriClip platform, with ease of use and design simplicity that offers enhanced access and increased visibility for physicians.
 
“The AtriClip FLEX-Mini is an unparalleled product that reinforces our position as the market leader in surgical LAA management,” AtriCure President/CEO Michael Carrel said. “With nearly 600,000 AtriClip devices sold globally, we are having a significant impact on patients’ lives. Continuing to innovate and enhance the unique features of our AtriClip platform will support even greater growth in this market.” 
 
The AtriClip FLEX-Mini incorporates the trusted elements of the AtriClip portfolio, featuring a fully enclosed design with parallel beams for continuous closing force, ensuring optimal pressure on atrial tissue. The low-profile design enhances visibility without compromising stability, providing physicians with unprecedented control during procedures. Additionally, the device’s ergonomic handle design enables single-handed placement, further simplifying the application process.
 
“The AtriClip FLEX-Mini is a significant step forward in ensuring patients receive the best possible treatment,” said Ibrahim S. Sultan, M.D., professor and chief, Division of Cardiac Surgery, University of Pittsburgh Medical Center. “This device builds off the first- and second-generation platforms, which established an incredible record of clinical outcomes. With surgical LAA management now having the highest-level recommendation for treatment from multiple physician societies, this new technology will make it even easier for my surgeon colleagues to choose mechanical appendage closure.”
 
AtriCure Inc. provides technologies for treating Afib and related conditions. Afib affects more than 37 million people globally. Electrophysiologists, cardiothoracic and thoracic surgeons worldwide use AtriCure technologies for treating Afib, reducing Afib-related complications, and post-operative pain management. AtriCure’s Isolator Synergy Ablation System is the first medical device to receive FDA approval for treating persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.